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Lenvatinib is a molecular targeted drug used in the treatment of patients with unresectable thyroid cancer. We present a case
of medication-related osteonecrosis of the jaw (MRONJ), which occurred in a patient receiving lenvatinib therapy and which
was treated by surgical management. The objectives of this paper are to highlight the possibility of MRONJ being associated
with lenvatinib and to accumulate knowledge regarding the management and treatment of MRONJ associated with antiangio-
genic drugs. The patient’s past medical history included thyroid follicular carcinoma with multiple bone metastasis diagnosed
in 2013. Lenvatinib was used on the patient in July 2015 for the treatment of thyroid follicular carcinoma. Three months after
the start of the lenvatinib drug holiday, a sequestrectomy involving the extraction of the lower right canine and upper left first
premolar was performed under general anesthesia. The patient maintained lenvatinib therapy and when a follow-up was made
five months after sequestrectomy, the wound showed complete mucosal healing. Levatinib is related to MRONJ and its de-
velopmental mechanism might be caused by inhibition of angiogenesis targeting vascular endothelial growth factor receptor.
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Introduction
Lenvatinib is a molecular targeted drug used in the treat-
ment of patients with unresectable thyroid cancer. It acts
by inhibiting the multiple receptor tyrosine kinases, tar-
geting vascular endothelial growth factor receptors, fi-
broblast growth factor receptors, and platelet growth fac-
tor receptor α.１，２ Currently, various molecular targeted
drugs have been developed and put into practical use for
the clinical management of unresectable cancers. More
than ten years have passed since the first reported
bisphosphonate-related osteonecrosis of the jaw
(BRONJ) case in 2003.
３
Afterwards, denosumab-related
osteonecrosis of the jaw (DRONJ) was also reported.
４
Al-
though denosumab has entirely different mechanisms in
preventing osteoclast-mediated bone resorption from the
bisphosphonates, osteonecrosis of the jaw (ONJ) cases
have also been described in patients taking denosumab at
approximately the same frequency as BRONJ.
５，６
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Figure　1　Schematic timeline of medication history and oral symptoms.
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Figure　2　An intraoral finding during the first inspection. A den-
tal fistula on the buccal surface of the lower right premolar region
(indicated by an arrow).
gery (AAOMS) defined medication-related osteonecrosis
of the jaw (MRONJ) to accommodate the growing num-
ber of osteonecrosis cases involving the maxilla and
mandible associated with other antiresorptive and antian-
giogenic therapies.
７
Recent reports have demonstrated
that molecular targeted drugs have the potential to con-
tribute to the development of ONJ, but reported cases of
MRONJ are insufficient.
８-１３
The long-term side effects of
new molecular targeted drugs should be explored.
The objectives of this paper are to highlight the possi-
bility of MRONJ being associated with lenvatinib and to
accumulate knowledge regarding the management and
treatment of MRONJ associated with antiangiogenic
drugs. We present a case of MRONJ in a patient receiv-
ing lenvatinib therapy which was successfully treated by
surgical management.
Case report
A 62-year-old woman presented to the Department of
Oral and Maxillofacial Surgery at Tokyo Women’s
Medical University Hospital with complaints of swelling
and pain of gingiva involving the lower right first and
second premolar region in January 2016. The patient’s
past medical history included thyroid follicular carci-
noma with multiple bone metastasis diagnosed in 2013,
postoperative treatment of sigmoid colon cancer in 2015,
and hypertension. The patient had been treated with len-
vatinib in July 2015 for the thyroid follicular carcinoma.
Furthermore, the patient had been treated once with zole-
dronate from August 2013 to October 2014 and with
sorafenib from October 2014 to April 2015. There was
no history of radiation therapy on the head and neck re-
gion (Figure 1 ) . Approximately fifteen months have
passed since the start of the lanvatinib treatment.
Upon physical examination, there was neither facial
swelling or neck lymphadenopathy.
Examination of the oral cavity revealed a dental fistula
on the buccal surface of the lower right premolar region,
but there was no obvious pus discharge (Figure 2). This
lesion had a swelling of gingiva and was painful on pal-
pation. Panoramic radiograph examination revealed the
presence of radiolucencies around the tooth roots of the
lower right premolars and canine (Figure 3).
Three months after the initial presentation, exposed
bone and pus discharge were observed in the left maxilla.
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Figure　3　A panoramic radiograph revealed the presence of ra-
diolucencies around tooth roots of the lower right premolars and 
canine (indicated by an arrow).
Figure　4　Computed tomography (CT) images and the panoram-
ic radiograph of extensive osteolysis with squestrum in the right 
mandible and left maxilla (indicated by arrows).
Figure　5　Intraoral findings and a panoramic radiograph six
months after tumor resection. The mucosa is healed without bone 
exposure.
Five months after the bone exposure appearance, the pa-
tient presented to our department for acute swelling and
pain of the right mandible. The patient’s oncologist had
suspended the lenvatinib therapy until the patient could
be dentally cleared.
Under local anesthesia, extraction of the lower right
first and second premolars was performed and the ne-
crotic bone parts surrounding the premolars were re-
moved. The lenvatinib therapy restarted one month later.
However, due to the exacerbation of swelling and pus
discharge in the right mandible lesion, it was suspended
again. Three months after the drug holiday, computed to-
mography (CT) scan revealed extensive osteolysis with
sequestrum in the right mandible and left maxilla (Fig-
ure 4). Sequestrectomy involving the extraction of the
lower right canine and upper left first premolar was per-
formed under general anesthesia. Two months post-
operation, the lenvatinib therapy was restarted. The pa-
tient has maintained the lenvatinib therapy and when a
follow-up was made four months after the sequestrec-
tomy, the wound showed complete mucosal healing (Fig-
ure 5).
Discussion
AAOMS defines MRONJ as a mucosal lesion of the
maxillofacial region with necrotic bone exposure. This
exposure should be at least eight weeks old and occur in
patients receiving antiresorptive or antiangiogenic
agents.
７
The patient here had necrotic bone exposure for
more than eight weeks and had no history of radiation
therapy on the head and neck region.
Therefore, the case was considered as MRONJ. Fur-
thermore, the staging and treatment strategies of MRONJ
were defined by AAOMS
７
: in the present case, the ex-
posed necrotic bone extending beyond the region of the
alveolar bone, ramus in the right mandible, osteolysis ex-
tending to the inferior border of the mandible by the ra-
diographs. As a stage-specific treatment of stage 3
MRONJ, debridement in combination with antibiotic
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therapy is recommended.
７
Moreover, sequestrectomy and
antibiotic therapy were also performed.
There are several case reports regarding MRONJ pa-
tients who received novel antiangiogenic drug therapies
for cancer, such as tyrosine kinase inhibitors and mono-
clonal antibody-targeting vascular endothelial growth
factor (VEGF).
７-１３
In the present case, the patient was ex-
posed to three kinds of medicine which were considered
to have contributed to the development of MRONJ: (1)
zoledronate from August 2013 to October 2014, ( 2 )
sorafenib from October 2014 to April 2015, and (3) len-
vatinib from July 2015 until the time of this writing. Len-
vatinib is an oral inhibitor of multiple receptor tyrosine
kinases targeting vascular endothelial growth factor re-
ceptor (VEGFR) 1-3, fibroblast growth factor receptor
( FGFR ) 1-4, and platelet growth factor receptor
(PDGFR) α.１ Tyrosine kinase inhibitors have anticancer
potency to treat solid tumors, including gastrointestinal
stromal tumors, small cell lung cancer, thyroid carcinoma
and hematologic malignancies.
１４
To the best of our
knowledge, no case of MRONJ occurring during len-
vatinib therapy has been reported so far.
On the other hand, sorafenib is also a small molecule
that inhibits the receptor tyrosine kinase activity of
VEGFRs 1-3 and PDGFR β.８ Some cases of osteonecro-
sis observed during sorafenib therapy have been reported
in mandibular and femoral heads.
９
In the present case, the
sorafenib therapy was performed for six months and was
completed ten months before the first visit to our depart-
ment. As a unique feature of the present case report, the
patient received two types of antiangiogenic drug treat-
ment (lenvatinib and sorafenib) after zoledronate treat-
ment for ten months. Although the patient did not un-
dergo any surgical dental treatment during either antian-
giogenic drug therapies, the MRONJ developed by multi-
ple influence of the medications.
In a previous report, the risk of ONJ in patients with
cancer exposed to bevacizumab, a molecular targeted
drug and an antiangiogenic agent, was 0.2% (20 cases
per 10,000), but the risk in patients exposed to bevacizu-
mab and zoledronate was higher (0.9%; 90 cases per
10,000).
１５
Therefore, in the present case, the highly po-
tent multi-kinase inhibitors were the probable agents to
have been responsible for the development of osteone-
crosis of the jaw. Osteonecrosis is classically considered
as an interruption in vascular supply or avascular necro-
sis thus, it is not surprising that inhibition of angiogenesis
is a leading hypothesis in ONJ pathophysiology.
７
In the present case, the patient had a perioperative drug
holiday three months before and two months after the se-
questrectomy under general anesthesia. This drug holiday
was not only for the surgical operation, but also because
of the side effects of lenvatinib and the radiation therapy
for bone metastasis. Four months after the sequestrec-
tomy, the soft tissue healing was completed in the upper
and lower jaws (Figure 5). Until the time of this writing,
while the patient is still on lenvatinib medication, there is
no evidence of recurrence. We believe that surgical inter-
vention was appropriate after a drug holiday, considering
sequestrum had formed.
In conclusion, similar to many other molecular tar-
geted drugs for cancer, lenvatinib is related to MRONJ
and its developmental mechanism might be caused by in-
hibition of angiogenesis targeting vascular endothelial
growth factor receptor.
７，９，１１，１４
In addition, there is a possi-
bility that lenvatinib therapy can independently contrib-
ute to the development of MRONJ, like sunitinib and
sorafenib.
９，１１，１３
Further investigation is needed to evaluate
a possible relationship between lenvatinib and MRONJ.
In recent years, a wide variety of molecular targeted
drugs have been put to practical use for cancer treatment,
but their long-term side effects are still unclear. Specifi-
cally, there is a possibility that new molecular targeted
drugs can induce ONJ when combined with antiresorp-
tive agents. It is important to report the side effects of
new molecular targeted drugs and strive to quickly iden-
tify and prevent them.
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